Research Projects All Projects

Quick links

Development of the prototype of new universal Hepatitis B recombinant vaccine

Project is being carried out within the ERDF activity „Support for Science and Research”  
Project agreement Nr. 2010/0211/2DP/
Project duration: 36 months (01.10.2010.-30.09.2013.)
Project costs: 369872 LVL
Principal investigator: Dr. biol. Andris Dišlers

Specific aim of the project

Development of new Hepatitis B vaccine prototype on the basis of HBV core-antigen HBcAg and preS1, and technology for production of recombinant HBcAg-preS1 virus-like particles (VLPs) with high purity standard.

Activities implemented during the project:

1. Industrial research - development of new product – prototype of universal Hepatitis B vaccine.

1.1. Design of HBcAg-preS1 expression vectors, construction and selection of optimal variants.

1.2. Research to find the principles of chimeric HBcAg-preS1 VLP purification.

1.3. Immunological testing of vaccine prototype.

1.4. Test of virus-neutralising activity of HBcAg-preS vaccine prototype.

2. Experimental development – technology development for chimeric HBc-preS VLP obtaining

2.1. Producer strain optimization.

2.2. Optimization of cultivation conditions and biomass production.

2.3. Development of purification protocol for chimeric HBcAg-preS1 VLPs.

2.4. End product characterization, validation and formulation of product.

As a result of the project, the following will be developed:

New product: Prototype of universal Hepatitis B virus vaccine

New technology: Technology for chimeric HBc-preS VLP obtaining

Mājas lapas izstrādi finansēja ERAF aktivitātes projekts Nr. 2010/0196/2DP/ "Latvijas biomedicīnas pētījumu integrācija Eiropas zinātnes telpā".